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KidneyCardiovascular Risk Factors Accelerate
Kidney Function Decline in PostLMyocardial
Infarction Patients: The Alpha Omega Cohort Study
Kevin Esmeijer1,2, Johanna M. Geleijnse3, Johan W. de Fijter1, Erik J. Giltay4,
Daan Kromhout3,5 and Ellen K. Hoogeveen1,2,6
1Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands; 2Department of Clinical Epidemi-
ology, Leiden University Medical Center, Leiden, The Netherlands; 3Division of Human Nutrition, Wageningen University,
Wageningen, The Netherlands; 4Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands;
5Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands; and 6Department of
Nephrology, Jeroen Bosch Hospital, Den Bosch, The NetherlandsIntroduction: Impaired kidney function is a robust risk factor for cardiovascular mortality. Age-related
annual kidney function decline of 1.0 ml/min per 1.73 m2 after age 40 years is doubled in
postmyocardial infarction (MI) patients.
Methods: We investigated the impact of the number of cardiovascular risk factors (including unhealthy
lifestyle) on annual kidney function decline, in 2426 post-MI patients (6080 years) of the prospective
Alpha Omega Cohort study. Glomerular ﬁltration rate was estimated by serum cystatin C (eGFRcysC) and
combined creatininecystatin C (eGFRcr-cysC), using the Chronic Kidney Disease Epidemiology Collabo-
ration (CKD-EPI) equations from 2012. Data were analyzed by multivariable linear and logistic regression.
Results: At baseline,mean (SD) eGFRcysC and eGFRcr-cysCwere 81.5 (19.6) and 78.5 (18.7)ml/min per 1.73m
2,
respectively. Of all patients, 79% were men, 19% had diabetes, 56% had high blood pressure ($140/90
mmHg), 16%were current smokers, 56% had high serum low-density lipoprotein (LDL of$2.5mmol/l), and
23% were obese (body mass index of $30.0 kg/m2). After multivariable adjustment, the additional annual
eGFRcysC decline (95% conﬁdence interval) was as follows: in patients with versus without diabetes, 0.90
(1.23 to 0.57) ml/min per 1.73 m2; in patients with high versus normal blood pressure, 0.50 (0.76
to 0.24) ml/min per 1.73 m2; in obese versus nonobese patients, 0.31 (0.61 to 0.01) ml/min per 1.73 m2;
and in current smokers versus nonsmokers, 0.19 (0.54 to 0.16) ml/min per 1.73 m2. High LDL was not
associated with accelerated eGFRcysC decline. Similar results were obtained with eGFRcr-cysC.
Conclusion: In older, stable post-MI patients without cardiovascular risk factors, the annual kidney function
decline was 0.90 (1.16 to 0.65) ml/min per 1.73 m2. In contrast, in post-MI patients with $3 cardio-
vascular risk factors, the annual kidney function decline was 2.5-fold faster, at 2.37 (2.85 to 1.89)
ml/min per 1.73 m2.
Kidney Int Rep (2018) 3, 879–888; https://doi.org/10.1016/j.ekir.2018.03.005
KEYWORDS: cardiovascular risk factors; kidney function decline; lifestyle
ª 2018 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).T he incidence of chronic kidney disease (CKD) showsan increasing trend worldwide.1 Impaired kidney
function is a robust and independent risk factor for
cardiovascular and all-cause morbidity and mortality.2
In industrialized countries, in healthy individuals after
age 40 years, kidney function gradually declines
annually about 0.8 to 1.0 ml/min per 1.73 m2.3,4 In
contrast, postmyocardial infarction (MI) patients
have an accelerated kidney function decline of aboutspondence: Kevin Esmeijer, Department of Nephrology,
University Medical Center (Building 1, C7-Q), Albinusdreef
3 ZA Leiden, The Netherlands. E-mail: k.esmeijer@lumc.nl
ved 7 December 2017; revised 16 February 2018; accepted 12
2018; published online 16 March 2018
International Reports (2018) 3, 879–8882.2 ml/min per 1.73m2 per year, and are thus more prone
to developing CKD.5
Classic modiﬁable cardiovascular risk factors such as
hypertension and diabetes are important drivers for the
development of CKD.6–10 The association between
elevated low-density lipoprotein (LDL) levels and kid-
ney function decline is less clear.11 Lifestyle factors,
such as cigarette smoking and adiposity, may increase
the risk of hypertension and diabetes. All previously
mentioned cardiovascular risk factors can have an un-
favorable effect on kidney function owing to increased
inﬂammation, oxidative stress, endothelial dysfunction,
and disturbed coagulation. For example, accumulation
of visceral adipose tissue may lead to increased879
CLINICAL RESEARCH K Esmeijer et al.: Cardiovascular Risk Factors and Kidney Function Declineproduction of inﬂammatory mediators by adipocytes,
which may contribute to glomerular and interstitial
ﬁbrosis.12,13
Survival after MI has been improving, as a result of
improved health care and pharmaceutical treatment.
These trends, together with the global tendency toward
a less healthy lifestyle and population aging, have
resulted in a considerable pool of patients at high risk for
CKD.14 Little is known about the beneﬁcial effect of
optimal treatment of cardiovascular risk factors and
healthy lifestyle on kidney function decline in post-MI
patients. Because adequate drug treatment of cardio-
vascular risk factors and modest lifestyle alterations are
achievable and may retard kidney function decline in
post-MI patients, we studied the association of modiﬁ-
able cardiovascular risk factors (including lifestyle) in




This is a secondary analysis of the prospective Alpha
Omega Cohort Study (ClinicalTrials.gov no.
NCT03192410). We included patients from the Alpha
Omega Trial, a randomized, controlled, multicenter
trial of omega-3 (n-3) fatty acids supplementation in
4837 patients with a veriﬁed history of MI. Patients
were 60 to 80 years of age and were receiving state-of-
the-art antihypertensive, antithrombotic, and lipid-
modifying drug treatment, according to international
guidelines, as described elsewhere.15,16 The trial started
in 2002 and ended in 2009. Patients with severe heart
failure (New York Heart Association [NYHA] stage IV)
were excluded. For the present observational study,
patients were selected from whom nonfasting blood
was drawn at baseline and after 41 months. Owing to
ﬁnancial constraints, 2 blood samples were available
only for 2426 patients (50% of the cohort, i.e., those
randomized before August 2005). Of all patients ran-
domized before August 2005 [n ¼ 2918], 233 patients
died during follow-up, and 259 patients had missing
blood samples or refused participation (Supplementary
Figure S1). This study was conducted in accordance
with the Declaration of Helsinki and was approved by a
central medical ethics committee in the Netherlands.
Written informed consent was obtained from all
patients. Design and reporting of the current study was
performed in accordance with the Strengthening The
Reporting of OBservational Studies in Epidemiology
(STROBE) Statement for cohort studies.17
Data Collection
Patients were interviewed and physically examined by
trained research nurses at baseline and after 41 months.880Standardized blood handling procedures for the Alpha
Omega Trial are described in detail elsewhere.18,19
Lipid, glucose, and high-sensitivity C-reactive protein
(hsCRP) levels were determined as described else-
where.20 Information on demographic variables, life-
style habits, current health status, and medical history
were collected by self-administered questionnaires as
previously described in detail.18 Questionnaires were
checked by research nurses. Information on smoking of
cigarettes was obtained by self-reported questionnaires
and was dichotomized into current smoking versus
nonsmoking (former or never smoking). Alcohol con-
sumption was dichotomized into $1 glass per week
versus <1 glass per week. Systolic and diastolic blood
pressure (ﬁrst and ﬁfth Korotkoff sounds, respectively)
were measured at the left upper arm with the patient
seated, after a 10-minute seated rest, using an automatic
device (Omron HEM-711, Omron Healthcare Europe
B.V., Hoofddorp, The Netherlands). The average of 2
blood pressure measurements was taken. High blood
pressure was deﬁned as inadequately controlled blood
pressure according to the latest recommendations of the
international guideline of the European Society of
Cardiology (systolic blood pressure $140 mm Hg or
diastolic blood pressure $90 mm Hg).21 Diabetes mel-
litus was considered to be present in case of a self-
reported physician diagnosis, use of glucose-lowering
drugs, and/or hyperglycemia. Hyperglycemia was
deﬁned as serum glucose of $7.0 mmol/l for patients
who had fasted 4 hours or $11.1 mmol/l for nonfasting
patients. Serum LDL was calculated using the Friede-
wald formula.22 High LDL was deﬁned as serum level
of $2.5 mmol/l.23 Body mass index (BMI) was calcu-
lated as weight in kilograms divided by the square of
height in meters. Obesity was deﬁned as a BMI $ 30.0
kg/m2, according to World Health Organization
guidelines.24 Medication was coded according to the
Anatomical Therapeutic Chemical (ATC) Classiﬁcation
System.
Kidney Function Assessment
At baseline and 41-month follow-up, serum cystatin C
(cysC) was measured from stored blood samples in a
central laboratory.We used calibrators and assays of the
same lot code, which was stable (no downward drift).25
Serum creatinine (cr) was measured by the modiﬁed
kinetic Jaffé method, as previously described in detail.25
We estimated glomerular ﬁltration rate based on cystatin
C (eGFRcysC) and combined creatininecystatin
C (eGFRcr-cysC) at baseline and after 41 months, using
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equations from 2012, taking into account age,
sex, and race.26 Both eGFRcysC and eGFRcr-cysC are
regarded as superior measures of kidney functionKidney International Reports (2018) 3, 879–888
K Esmeijer et al.: Cardiovascular Risk Factors and Kidney Function Decline CLINICAL RESEARCHcompared to eGFR based on creatinine alone. In the main
analyses, we use eGFRcysC as outcome; results for
eGFRcr-cysC as outcome are reported in Supplementary
Tables S1 to S3. From each individual, eGFR decline
was calculated by subtracting the eGFR at baseline from
the eGFR after 41months. Assuming a linear decline over
time, we then estimated the annual kidney function
decline. Rapid kidney function decline was deﬁned as an
annual decline of >3 ml/min per 1.73 m2.27,28
Data Analysis
Baseline characteristics are presented for all patients and
according to the number of cardiovascular risk factors.
Baseline data are presented as mean (SD), median (inter-
quartile range), or number (percentage) when appro-
priate. The following data were missing: LDL cholesterol
(n ¼ 116), BMI (n ¼ 4), level of education (n ¼ 4), blood
pressure (n ¼ 3), and alcohol consumption (n ¼ 3). We
accounted for missing data by multiple imputation,
using 5 imputations, and including all relevant baseline
variables and the outcome in the model.
We used analysis of covariance to compare annual
eGFRcysC decline rates for presence versus absence of a
prioriselected cardiovascular risk factors (including
unhealthy lifestyle): diabetes, high blood pressure,
high LDL levels, current cigarette smoking, and
obesity. In addition, we used multivariable logistic
regression to estimate for each cardiovascular risk
factor the risk of rapid kidney function decline. In all
analyses, we used patients without the cardiovascular
risk factor as the reference. All analyses are presented
crude and adjusted for potential confounders: age, sex,
and 3 dummy variables for the four n-3fatty acid
treatment groups of the Alpha Omega Trial (model 1).
In model 2 we adjusted in addition to model 1, for
alcohol use (<1 vs. $1 glass per week), level of edu-
cation (3 dummy variables), and the 5 a prioriselected
cardiovascular risk factors. Analyses for obesity were
not adjusted for diabetes, high blood pressure, and
high LDL, because these factors are in the causal
pathway between obesity and kidney function decline.
Analyses were not adjusted for baseline eGFR, because
baseline adjustment in models with change scores as
dependent variable results in biased and inﬂated esti-
mates.29 We explored the presence of effect modiﬁca-
tion between age or sex and the modiﬁable risk factors
with regard to kidney function decline by including
interaction terms in our linear regression models.
Furthermore, we repeated analyses in strata of baseline
eGFR (eGFR <60, 60 to <90, $90 ml/min per 1.73 m2).
Finally, we calculated the rate of kidney function
decline and risk of rapid kidney function decline
according to the number of cardiovascular risk factors
present in each patient. In these analyses, we includedKidney International Reports (2018) 3, 879–888diabetes, high blood pressure, current smoking, and
obesity. High LDL was excluded because of lack of
evidence that modifying LDL level affects cardiovas-
cular risk.30 Patients without cardiovascular risk
factors have, by deﬁnition, an optimal cardiovascular
risk proﬁle and a healthy lifestyle (e.g., are considered
being optimally treated for the included risk factors
according to the latest guidelines of the European
Society of Cardiology: blood pressure <140/90 mm Hg,
no diabetes, never smoked cigarettes or ceased smok-
ing, and no obesity (BMI <30 kg/m2).31 A linear trend
was evaluated by including a variable representing
number of cardiovascular risk factors into the linear
regression model.
Sensitivity Analyses
We repeated all analyses without multiple imputation,
using a complete case analysis. Next, we repeated the
analyses adjusting for continuous instead of dichoto-
mized variables, for example, for BMI instead of
obesity, and for systolic blood pressure instead of high
blood pressure. Main analyses were repeated after
adjustment for time since MI, hsCRP levels, or use of
reninangiotensin system (RAS)blocking drugs. We
repeated the analyses in patients persistently (at base-
line and after 41 months of follow-up) using RAS-
blocking drugs. Finally, we repeated the main
analyses using eGFRcr-cysC as outcome. In these ana-
lyses, we excluded 82 patients for whom serum creat-
inine was not available because of technical failure or
analytical disturbance.25 We considered 2-sided P
values <0.05 statistically signiﬁcant. All analyses were
performed using SPSS 23.0 (SPSS, Inc., Chicago, IL).RESULTS
Baseline Characteristics
Baseline characteristics of all patients (n ¼ 2426), and
stratiﬁed for the number of cardiovascular and lifestyle
risk factors, are presented in Table 1. The mean (SD) age
of the total study cohortwas 68.9 (5.4) years, 79.4%were
men, median time since MI was 4.0 years, and mean (SD)
eGFRcysC and eGFRcr-cysC were 81.5 (19.6) and 78.5 (18.7)
ml/min per 1.73 m2, respectively. Of all patients, 23%
were obese, 16% were current smokers, 67% were
former smokers, 44% had a blood pressure within the
target range, 87% used antihypertensive medication,
54% used RAS-blocking drugs (of whom 92% persisted
on RAS-blocking drugs), and 19% had diabetes (of
whom 71% used glucose-lowering medication). Finally,
44% of patients had normal LDL and 85% used statins
(of whom 95% persisted on statins). Of all patients with
high LDL (n¼ 990) at baseline, 10% started with a statin
during follow-up.881
Table 1. Baseline characteristics of 2426 post-MI patients of the Alpha Omega Cohort according to the number of cardiovascular risk factors













Age, yr 68.9  5.4 68.3  5.3 69.6  5.4 68.5  5.5 68.9  5.4
Men, n (%) 1927 (79.4) 497 (83.1) 878 (80.7) 430 (75.0) 122 (73.1)
Race, white, n (%) 2398 (98.8) 589 (98.5) 1078 (99.1) 567 (99.0) 164 (98.2)
Time since MI, yr 4.0 (2.0–6.4) 3.3 (1.6–5.9) 4.0 (1.9–6.5) 4.4 (2.4–6.6) 4.8 (3.1–7.4)
Educational level, n (%)
Only elementary/low 1374 (57.0) 319 (53.6) 603 (55.7) 353 (62.0) 99 (59.6)
Moderate 738 (30.6) 190 (31.9) 344 (31.8) 152 (26.7) 52 (31.3)
Higha 300 (12.4) 86 (14.5) 135 (12.5) 64 (11.2) 15 (9.0)
Current smoking, n (%) 386 (15.9) 0 100 (9.2) 196 (34.2) 90 (53.9)
Alcohol consumption,b n (%) 1759 (72.5) 450 (75.3) 813 (74.7) 390 (68.1) 106 (63.5)
Obesity,c n (%) 554 (22.8) 0 146 (13.4) 268 (46.8) 140 (83.8)
Body mass index, kg/m2 27.7  3.6 26.0  2.3 27.1  3.1 29.3  4.1 32.1  3.5
High blood pressure,d n (%) 1064 (43.9) 0 744 (68.4) 457 (79.8) 161 (96.4)
Systolic blood pressure, mm Hg 143.3  21.4 125.1  10.3 147.6  21.6 150.8  19.6 154.8  17.7
Diastolic blood pressure, mm Hg 81.4  10.8 75.1  7.8 83.1  10.9 83.2  10.8 86.3  9.4
Antihypertensive drugs,e n (%) 2111 (87.0) 502 (83.9) 954 (87.7) 507 (88.5) 148 (88.6)
ACE inhibitors/ATII blockers 1309 (54.0) 311 (52.0) 576 (52.9) 327 (57.1) 95 (56.9)
b-Blockers 1585 (65.3) 371 (62.0) 718 (66.0) 385 (67.2) 111 (66.5)
Calcium channel blockers 467 (19.2) 111 (18.6) 200 (18.4) 117 (20.4) 39 (23.4)
Diuretics 500 (20.6) 99 (16.6) 198 (18.2) 162 (28.3) 41 (24.6)
Diabetes,f n (%) 449 (18.5) 0 98 (9.0) 225 (39.3) 126 (75.4)
Plasma glucose,g mmol/l 6.0  2.0 5.4  1.0 5.7  1.4 6.7  2.4 8.2  3.2
Glucose-lowering drugs,h n (%) 320 (13.2) 0 72 (6.6) 169 (29.5) 79 (47.3)
Oral glucose-lowering drugs 253 (10.4) 0 56 (5.1) 135 (23.6) 62 (37.1)
Insulin analogues 107 (4.4) 0 25 (2.3) 52 (9.1) 30 (18.0)
Serum LDL,i mmol/l 2.74  0.80 2.68  0.81 2.74  0.79 2.75  0.79 2.86  0.87
Lipid-modifying drugs,j n (%) 2089 (86.1) 518 (86.6) 938 (86.2) 485 (84.6) 148 (88.6)
Statins 2073 (85.4) 516 (86.3) 933 (85.8) 478 (83.4) 146 (87.4)
Antithrombotic agents,k n (%) 2368 (97.6) 583 (97.5) 1060 (97.4) 560 (97.7) 165 (98.8)
Serum hsCRP, mg/l 1.7 (0.8–3.6) 1.2 (0.6–2.8) 1.5 (0.8–3.3) 2.3 (1.1–4.6) 2.9 (1.2–5.2)
Serum cystatin C, mg/l 0.97  0.24 0.93  0.20 0.97  0.24 1.01  0.28 0.97  0.24
Serum creatinine,l mmol/l 90.1 29.3 89.2  25.0 90.0  30.4 92.7  32.1 82.1  26.1
eGFRcysC,
m ml/min per 1.73 m2 81.5  19.5 84.9  17.9 81.0  19.3 78.7  20.8 81.7  20.5
eGFRcr-cysC,
m ml/min per 1.73 m2 78.5  18.7 80.8  17.1 78.4  18.6 75.8  19.8 80.1  19.7
ACE, angiotensin-converting enzyme; ATII, angiotensin II; eGFRcr-cysC, glomerular filtration rate estimated by combined creatininecystatin C; eGFRcysC, glomerular filtration rate
estimated by serum cystatin C; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; MI, myocardial infarction.
aHigher vocational education or university.
bAt least 1 glass per week.
cBody mass index $30 kg/m2.
dSystolic blood pressure of $140 mm Hg and/or diastolic blood pressure of $90 mm Hg, irrespective of use of blood pressurelowering drugs.
eBlood pressurelowering drugs: Anatomical Therapeutic Chemical Classification System (ATC) codes C02, C03, C07, C08, and C09.
fSelf-reported diagnosis by a physician, use of glucose-lowering drugs, or hyperglycemia.
gTo convert the values for glucose to milligrams per deciliter (mg/dl), divide by 0.05551.
hGlucose-lowering drugs: ATC codes A10, A10A, A10B, A10X.
iTo convert the values for LDL-cholesterol to milligrams per decilitre (mg/dl), divide by 0.02586.
jLipid-modifying drugs: ATC codes C10 and C10AA.
kAntithrombotic agents: ATC code B01.
lTo convert the values for creatinine to milligrams per decilitre (mg/dl), divide by 88.40.
meGFRcysC and eGFRcr-cysC based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations from 2012.
Data are reported as number of patients (%), mean  SD, or median (interquartile range).
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After 41 months of follow-up, the mean (95% conﬁdence
interval [CI]) eGFRcysC decline for all patients was 4.62
(5.06 to 4.18) ml/min per 1.73 m2, corresponding to
an annual decline of 1.34 (1.47 to 1.21) ml/min per
1.73 m2. Men and women had annual kidney function
decline rates of1.45 (1.59 to1.31) and0.91 (1.19
to 0.63) ml/min per 1.73 m2, respectively. Patients
882younger than 70 years versus those 70 years or older had
annual kidney function decline rates of 1.15 (1.32
to 0.98) and 1.60 (1.80 to 1.41) ml/min per 1.73
m2, respectively. After multivariable adjustment (model
2), patients without or with diabetes had an annual
eGFRcysC decline of 1.17 (1.31 to 1.03) and 2.07
(2.37 to 1.78) ml/min per 1.73 m2 (difference, 0.90
(1.23 to 0.57) (Table 2). Patients with normal or highKidney International Reports (2018) 3, 879–888
Table 2. Mean (95% CI) annual cystatin Cbased eGFR decline rates in 2426 post–myocardial infarction patients according to absence or
presence of cardiovascular risk factors
Risk factor n Crude Model 1 Model 2
Diabetes
No (reference) 1977 –1.17 (–1.31 to –1.03) –1.17 (–1.31 to –1.03) –1.17 (–1.31 to –1.03)
Yes 449 –2.06 (–2.36 to –1.77)b –2.10 (–2.40 to –1.81)b –2.07 (–2.37 to –1.78)b
Blood pressure
<140/90 mm Hg (reference) 1062 –1.01 (–1.20 to –0.82) –1.01 (–1.20 to –0.82) –1.01 (–1.20 to –0.82)
$140/90 mm Hg 1364 –1.59 (–1.76 to –1.42)b –1.51 (–1.69 to –1.34)b –1.51 (–1.69 to –1.34)b
Serum LDL
<2.5 mmol/l (reference) 990 –1.47 (–1.67 to –1.27) –1.47 (–1.67 to –1.27) –1.47 (–1.67 to –1.27)
$2.5 mmol/l 1436 –1.25 (–1.41 to –1.08) –1.29 (–1.46 to –1.12) –1.28 (–1.45 to –1.12)
Cigarette smoking
Nonsmoking (reference) 2040 –1.32 (–1.46 to –1.18) –1.32 (–1.46 to –1.18) –1.32 (–1.46 to –1.18)
Currently smoking 386 –1.43 (–1.75 to –1.11) –1.54 (–1.86 to –1.22) –1.51 (–1.83 to –1.18)
Body mass index
<30.0 kg/m2 (reference) 1871 –1.30 (–1.45 to –1.16) –1.30 (–1.45 to –1.16) –1.30 (–1.45 to –1.16)
$30.0 kg/m2 555 –1.46 (–1.72 to –1.19) –1.62 (–1.89 to –1.35)a –1.61 (–1.88 to –1.34)
CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; LDL, low-density lipoprotein.
aP < 0.05.
bP < 0.001 for difference between presence versus absence of risk factor.
Adjusted variables were ﬁxed at the mean value of the reference group; hence the estimates of the reference category are equal across models. Diabetes was deﬁned as self-reported
diagnosis by a physician, use of glucose-lowering drugs, or elevated plasma glucose level. Model 1: adjusted for age, sex, and treatment group. Model 2: model 1 plus additional
adjustment for current smoking, alcohol consumption, level of education, diabetes, high blood pressure, high LDL, and obesity. Analyses for obesity were not adjusted for diabetes, high
blood pressure, and high LDL.
Table 3. Odds ratios (95% CI) for risk of rapid eGFRcysC decline
(>3 ml/min per 1.73 m2 per year) in 2426 post–myocardial infarction
patients, for different cardiovascular risk factors
Risk factora Crude Model 1 Model 2
Diabetes 1.77 (1.41–2.21)b 1.79 (1.43–2.25)b 1.72 (1.36–2.17)b
High blood pressure 1.48 (1.22–1.79)b 1.41 (1.17–1.72)b 1.43 (1.18–1.74)b
High LDL 0.81 (0.67–0.98)c 0.82 (0.68–0.99)c 0.80 (0.66–0.98)c
Current cigarette
smoking
1.13 (0.88–1.45) 1.23 (0.95–1.58) 1.21 (0.94–1.57)
Obesity 1.09 (0.88–1.36) 1.17 (0.93–1.46) 1.15 (0.92–1.45)
CI, conﬁdence interval; eGFRcysC, glomerular filtration rate estimated by serum cystatin
C; LDL, low–density lipoprotein.
Diabetes was deﬁned as self–reported diagnosis by a physician, use of glucose–
lowering drugs, or hyperglycemia. High blood pressure was deﬁned as systolic blood
pressure of $140 mm Hg and/or diastolic blood pressure of $90 mm Hg, irrespective of
use of blood pressure lowering drugs. High LDL was deﬁned as serum LDL level of $2.5
mmol/l. Obesity was deﬁned as BMI of $30.0 kg/m2. Model 1: adjusted for age, sex, and
treatment group. Model 2: model 1 plus additional adjustment for current smoking,
alcohol consumption, level of education, diabetes, high blood pressure, high LDL, and
obesity. Analyses for obesity were not adjusted for diabetes, high blood pressure, and
high LDL.
aReference: absence of the risk factor of interest.
bP < 0.001.
cP < 0.05.
K Esmeijer et al.: Cardiovascular Risk Factors and Kidney Function Decline CLINICAL RESEARCHblood pressure had annual decline rates of1.01 (1.20
to0.82) and1.51 (1.69 to1.34) ml/min per 1.73 m2
(difference,0.50 ( 0.76 to0.24). Successive quartiles
of systolic blood pressure (quartile ranges: 86.5128.0,
128.5141.5, 142.0156.5, and 157.0237.5 mm Hg)
showed a faster annual kidney function decline: 0.99
(1.25 to0.74), 1.10 (1.34 to 0.85),1.45 (1.70
to 1.20), and 1.82 (2.07 to 1.57) ml/min per
1.73 m2, respectively. Each systolic blood pressure
increment of 10 mm Hg was associated with an extra
annual kidney function decline of 0.17 (0.23
to 0.12, P < 0.001) ml/min per 1.73 m2. We found a
weak U-shaped relation between diastolic blood pressure
and kidney function decline. Annual kidney function
decline for patients in the lowest through the highest
quartile was 1.33 (1.59 to 1.08), 1.15 (1.40
to 0.91), 1.32 (1.58 to 1.06), and 1.55 (1.80
to1.30)ml/min per 1.73m2 (quartile ranges: 44.073.5,
74.081.0, 81.588.0, and 88.5124.0 mm Hg). We
found no signiﬁcant difference in the rate of annual
kidney function decline between patients with high
compared to normal LDL levels. Cigarette smokers
compared to nonsmokers had an additional annual
eGFRcysC decline of 0.19 (0.54 to 0.16) ml/min per
1.73m2. Obesitywas associatedwith a 23% faster kidney
function decline (Table 2). We found no evidence for
effect modiﬁcation between sex, age, strata of baseline
kidney function, and the prespeciﬁed cardiovascular
risk factors with regard to eGFRcysC decline.
Of all patients, 573 (24.4%) had a rapid kidney func-
tion decline. Table 3 shows the odds ratios (ORs) for rapid
kidney function decline according to the aKidney International Reports (2018) 3, 879–888priori selected cardiovascular risk factors. Especially,
diabetes (OR 1.72 [1.362.17]) and high blood pressure
(OR 1.43 [1.181.74]) were strongly associated with
rapid kidney function decline. Associations for current
smoking (OR 1.21 [0.941.57]) and obesity (OR 1.15
[0.921.45]) were weaker. High LDLwas associatedwith
slower kidney function decline (OR 0.80 [0.660.98]).
Results were comparable when deﬁning rapid kidney
function decline as>5 ml/min per 1.73 m2 per year (data
not shown). Furthermore, after adjustment for age and
treatment group, men had a slightly higher risk of
rapid kidney function decline than women (OR 1.13
[0.89 1.43]). After adjustment for sex and treatment883
CLINICAL RESEARCH K Esmeijer et al.: Cardiovascular Risk Factors and Kidney Function Declinegroup, older compared to younger patients had more
often rapid kidney function decline (age $70 years
vs. <70 years, OR 1.32 [1.091.59]; age $75 years
vs. <75 years, OR 1.59 [1.252.02]).
Kidney Function Decline and Number of Risk
Factors
We calculated the annual kidney function decline and
risk for rapid kidney function decline in each patient
according to the number of cardiovascular risk factors,
namely, diabetes, high blood pressure, current ciga-
rette smoking, and obesity (BMI $ 30 kg/m2). Patients
without any of these cardiovascular risk factors present
(thus considered to have optimal cardiovascular pa-
rameters and a healthy lifestyle) had an annual kidney
function decline of 0.90 (1.16 to 0.65) ml/min per
1.73 m2 (Table 4, Figure 1). Each additional cardio-
vascular risk factor was associated with a progressively
faster annual kidney function decline (linear regression
coefﬁcient 0.45 [0.59 to 0.30] per additional risk
factor, P for linear trend <0.001). Patients in whom 3
or more cardiovascular risk factors were present had
an annual kidney function decline of –2.37 (–2.85
to –1.89) ml/min per 1.73 m2. Patients in whom all 4
cardiovascular risk factors (n ¼ 16) were present had
an annual kidney function decline of 4.59 (5.38
to 3.79) ml/min per 1.73 m2. Risk for rapid kidney
function decline increased progressively with every
additional cardiovascular risk factor (Table 4, Figure 1).
Patients with $3 cardiovascular risk factors had a
2.5-fold increased risk compared to patients without
any cardiovascular risk factors.
Sensitivity Analyses
Results did not materially change when using complete
cases only instead of multiple imputed data. Adjust-
ment with continuous instead of dichotomized vari-
ables did not change the results. Adjustment for timeTable 4. Mean (95% CI) annual eGFRcysC decline and odds ratios (95% C
presented per number of cardiovascular risk factorsa, in 2426 post–myoc
Number of risk factorsa n








CI, conﬁdence interval; eGFRcysC, glomerular filtration rate estimated by serum cystatin C.
aCardiovascular risk factors included diabetes, high blood pressure, obesity, and current smo
Adjusted variables were ﬁxed at the mean value of the reference group; hence the estimates of
diagnosis by a physician, use of glucose-lowering drugs, or hyperglycemia. High blood pressure
of$90 mm Hg, irrespective of use of blood pressurelowering drugs. Obesity was deﬁned as B
plus additional adjustment for alcohol consumption and level of education.
884since MI, serum hsCRP, or use of RAS-blocking drugs
yielded similar results. Conﬁning analyses to patients
who persistently used RAS-blocking drugs (n ¼ 1206)
yielded comparable associations. Analyses based on
eGFRcr-cysC as outcome showed slightly weaker effect
estimates (Supplementary Tables S1 and S2). The as-
sociation between the number of cardiovascular risk
factors and annual eGFRcr-cysC or eGFRcysC decline was
comparable (Supplementary Table S3).DISCUSSION
In a cohort of stable, older post-MI patients, we
showed that those patients with optimally treated
cardiovascular risk factors, including healthy lifestyle,
had an annual kidney function decline of about 0.90
ml/min per 1.73 m2. In contrast, post-MI patients with
3 or more suboptimally treated cardiovascular risk
factors had a 2.5-fold faster annual kidney function
decline of about 2.37 ml/min per 1.73 m2. We
recently showed that in these post-MI patients, an
eGFRcysC of <80 ml/min per 1.73 m
2 is a graded risk
factor for cardiovascular and all-cause mortality,
underlining the clinical relevance of these ﬁndings.2,28
The mean annual kidney function decline of 0.90
(1.16 to 0.65) ml/min per 1.73 m2 that we found in
optimally treated cardiac patients with a healthy life-
style is within the normal range of the age-related
kidney function decline in healthy individuals
of 1.0 ml/min per 1.73 m2.32–34 The mean (95% CI)
annual kidney function decline of all patients
was 1.34 (1.47 to 1.21) ml/min per 1.73 m2. Pre-
viously, the Prevention of Renal and Vascular Endstage
Disease (PREVEND) study showed, in post-MI patients,
an annual kidney function decline (95% CI) of 2.2
(5.0 to 0.9) ml/min per 1.73 m2.5 Post-MI patients in
the PREVEND study had a cardiovascular risk proﬁle
similar to that of patients in the Alpha Omega Cohort.Is) for rapid eGFRcysC decline (>3 ml/min per 1.73 m2 per year) are
ardial infarction patients of the Alpha Omega Cohort
Crude Model 1 Model 2
0 (–1.16 to –0.65) –0.90 (–1.16 to –0.65) –0.90 (–1.16 to –0.65)
9 (–1.48 to –1.10) –1.23 (–1.42 to –1.03) –1.23 (–1.42 to –1.03)
1 (–1.87 to –1.35) –1.66 (–1.92 to –1.40) –1.65 (–1.91 to –1.39)
6 (–2.74 to –1.77) –2.37 (–2.85 to –1.88) –2.37 (–2.85 to –1.89)
1 1 1
4 (0.89–1.46) 1.09 (0.85–1.40) 1.09 (0.85–1.40)
5 (1.18–2.03) 1.57 (1.19–2.06) 1.56 (1.19–2.06)
1 (1.66–3.49) 2.55 (1.77–3.71) 2.55 (1.75–3.71)
king.
the reference category are equal across models. Diabetes was deﬁned as self-reported
was deﬁned as systolic blood pressure of $140 mm Hg and/or diastolic blood pressure
MI of$30.0 kg/m2. Model 1: adjusted for age, sex, and treatment group. Model 2: model 1
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Figure 1. Annual eGFRcysC decline according to the number of cardiovascular risk factors, in 2426 post–myocardial infarction patients in the
Alpha Omega Cohort. For the 4 groups according to the number of cardiovascular risk factors (diabetes, high blood pressure, obesity, and
current smoking), the proportion (%) of the 4 different risk factors (columns, right vertical axis) and the mean (95% confidence interval [CI])
annual eGFRcysC decline (black line, left vertical axis), adjusted for age, sex, and treatment group, are presented. eGFR, estimated glomerular
filtration rate; eGFRcysC, glomerular filtration rate estimated by serum cystatin C.
K Esmeijer et al.: Cardiovascular Risk Factors and Kidney Function Decline CLINICAL RESEARCHThere are several explanations that may have resulted
in the higher annual kidney function decline in the
PREVEND compared to the Alpha Omega Cohort. First,
the small number (n ¼ 66) of post-MI patients in the
PREVEND study resulted in a wide 95% conﬁdence
interval, and, as a consequence, the effect estimate is
less precise. Patients from the Alpha Omega Cohort
participated in a trial for 41 months. Trial patients
generally are healthier and more compliant compared
to the general population, a phenomenon known as
volunteer bias.35 Finally, during follow-up, patients in
the Alpha Omega Cohort (20022009) have been more
strictly controlled according to more recent secondary
prevention guidelines, compared to patients in the
PREVEND cohort (19972005). In updated guidelines,
there was more attention given especially to patient
education, lifestyle monitoring (e.g., smoking cessa-
tion, weight management), diabetes and high blood
pressure management, more strict lipid regulation, and
standard prescription of statins and angiotensin-
converting enzyme inhibitors.36,37
In agreement with other studies, we found that dia-
betes and high blood pressure were strongly associated
with accelerated kidney function decline.7–10 Diabetes
may lead to diabetic nephropathy, a complex disease
characterized by hemodynamic, metabolic, and inﬂam-
matory changes, ultimately leading to progressive
interstitial ﬁbrosis and glomerular damage.38 High blood
pressure may cause increased intraglomerular pressure,
leading to endothelial dysfunction, loss of adequate
autoregulation, and eventually to progressive glomer-
ular and interstitial ﬁbrosis.39 We found a weakKidney International Reports (2018) 3, 879–888association between high LDL level and slower kidney
function decline, but this association may be distorted
by the fact that 85% of all patients used statins. More-
over, of all patients with high LDL at baseline, 10%
started with a statin during follow-up. Our ﬁnding is in
accordance with recent guidelines stating that CKD
patients$50 years of age should be treated with a statin
independent of lipid levels, without trying to reach a
target level.40 This paradigm shift is caused by the lack
of evidence linking changes in lipid levels with actual
cardiovascular risk and emerging evidence showing
pleiotropic effects of statins.30,41,42
In line with other studies, we found that obesity was
associated with faster kidney function decline.8,43
Obesity promotes deterioration of kidney function
through cardiovascular risk factors such as diabetes
and hypertension, and is also associated with visceral
fat accumulation and accompanying inﬂammation,
leading to glomerular and interstitial ﬁbrosis.12,13,24
Furthermore, we found that smoking of cigarettes
was associated with kidney function decline, which is
conﬁrmed by other studies.44 However, the association
of smoking and kidney function decline was weaker
than expected, and could be underestimated due to
underreporting, or so-called information bias.
Our study has some limitations. First, the observa-
tional design prevents us frommaking causal inferences.
Second, kidney function was estimated at only 2 time
points and was not directly measured. Third, we had no
information about proteinuria, an important indepen-
dent predictor of kidney function; therefore, we could
not study the association between optimal treatment of885
CLINICAL RESEARCH K Esmeijer et al.: Cardiovascular Risk Factors and Kidney Function Declinecardiovascular risk factors and change in proteinuria.
Fourth, about 17% of patients dropped out because of
missing samples, refusal of participation, or death. If
anything, this may have resulted in underestimation of
the associations that we found, as patients who dropped
out were most likely less healthy. Fifth, volunteer bias
may be present, as we included only trial patients.
However, because volunteering patients usually are
more healthy, we expect that this may have led to an
underestimation of our results. Finally, we analyzed
post-MI patients only, which may hamper the general-
izability of our results. Notably, the prevalence of car-
diovascular disease shows an increasing trend
worldwide, and our cohort of patients therefore repre-
sents a growing patient group.
A major strength of this study is our large homo-
geneous population of post-MI patients, which pro-
vides a unique opportunity to study the course of
kidney function decline in these patients. Second, we
used as outcomes both eGFRcysC and eGFRcr-cysC, which
are currently the most accurate methods available to
estimate kidney function.26,28,45
To conclude,we found a faster rate of kidney function
decline in post-MI patientswith an increasing number of
insufﬁciently treated cardiovascular risk factors
(including unhealthy lifestyle). Post-MI patients with
optimal cardiovascular and lifestyle parameters have an
annual kidney function decline comparable to that of the
general population. Further research is needed to
investigate whether optimization of cardiovascular risk
factors and healthy lifestyle may slow down the accel-
erated kidney function decline in post-MI patients.DISCLOSURE
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